MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma

Immune checkpoint blockade (ICB) has demonstrated an impressive outcome in patients with metastatic melanoma, yet, durable complete response; even with Ipilimumab/Nivolumab combo are under 30%. Primary and acquired resistance in response to ICB is commonly due to a tumor immune escape mechanism dict...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: de Azevedo, Ricardo A., Shoshan, Einav, Whang, Shanzhi, Markel, Gal, Jaiswal, Ashvin R., Liu, Arthur, Curran, Michael A., Travassos, Luiz R., Bar-Eli, Menashe
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7733907/
https://ncbi.nlm.nih.gov/pubmed/33344042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1846915
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars